CXCR4 and acute myeloid leukemia: Taken together, these results suggest that T22-PE24-H6 could be developed as a novel treatment applicable to around 50% of AML patients who overexpress CXCR4, especially when considering that high CXCR4 expression is associated with a poor prognosis in AML patients [12,13,14,15,16].